ZAI LAB LTD (ZLAB)
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
$22.80+3.83%
Close 2026-11-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
QuarterlyIQ Insights · ZLAB
How strong the business is — where it ranks within its sector on capital efficiency and cash generation, and how well management has been executing.
How this business ranks within health care on a research-validated quality screen. As of 2026-11-04.
The screen ranks ZLAB against its sector on four durable signals: share dilution, return on capital, free-cash-flow yield, and FCF margin. Historically the highest-quality names tended toward better typical outcomes and fewer bad years over multi-year holds (strongest at three years, modest at one), and that pattern showed up even before the price moved. It characterizes business quality, not price direction.
Each leg is a sector-relative percentile (higher is better); 3 of 4 legs were available for this name. The composite is built from these four; the raw value follows each percentile for context.
A forward quality tilt, not a price prediction, and context for your own research rather than a recommendation. Not investment advice.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 0 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated weak grew net income 29% of the time over the next year (vs 52% for the rest of the cohort, n=10118).
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
A guidance track record builds as the company issues and delivers on guidance.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
3 Anticipated Major Milestones in 2026 and the First Half of 2027 Global Pipeline Expected Clinical Developments and Data Readouts Zocilurtatug Pelitecan (zoci, DLL3-Targeting ADC; formerly ZL-1310)…
Stated in 2 of 2 supplied quarters. Management reported: “3 Anticipated Major Milestones in 2026 and the First Half of 2027 Global Pipeline Expected Clinical Developments and Data Readouts Zocilurtatug Pelitecan (zoci, DLL3-Targeting ADC; formerly ZL-1310) • First-Line Extensive-Stage Small Cell Lung Cancer (ES-SCLC): Report initial Phase 1 data evaluating zoci in combination with atezolizumab, with or without chemotherapy, at the European Society for Medical Oncology (ESMO) 2026 Congress in October 2026 and, subject to emerging data and regulatory discussions, initiate a registrational Phase 3 study in the second half of 2026.”
“3 Anticipated Major Milestones in 2026 and the First Half of 2027 Global Pipeline Expected Clinical Developments and Data Readouts Zocilurtatug Pelitecan (zoci, DLL3-Targeting ADC; formerly ZL-1310)…”
““During the quarter, we made strong progress advancing zoci, with AACR data reinforcing its differentiated profile in both SCLC and epNECs, collaborations with Amgen and Boehringer Ingelheim to evalu…”
This quarter, we sharpened our commercial focus, delivered sequential revenue growth, maintained commercial profitability, and laid the foundation for a return to meaningful growth in 2027.
Stated in 2 of 2 supplied quarters. Management reported: “This quarter, we sharpened our commercial focus, delivered sequential revenue growth, maintained commercial profitability, and laid the foundation for a return to meaningful growth in 2027.” “In the second half of the year, we expect to further stabilize product sales while laying the foundation for a return to meaningful growth in 2027.” Revenue was $106.311 million in 2026-Q2.
Zai Lab is preparing to seek inclusion of VYVGART Hytrulo in China’s National Reimbursement Drug List (NRDL) in 2027.
Stated in 2 of 2 supplied quarters. Management reported: “Zai Lab is preparing to seek inclusion of VYVGART Hytrulo in China’s National Reimbursement Drug List (NRDL) in 2027.” “Zai Lab is preparing to seek inclusion of KarXT in China’s NRDL in 2027.”
“Zai Lab is preparing to seek inclusion of VYVGART Hytrulo in China’s National Reimbursement Drug List (NRDL) in 2027.”
This quarter, we sharpened our commercial focus, delivered sequential revenue growth, maintained commercial profitability, and laid the foundation for a return to meaningful growth in 2027.
Stated in 2 of 2 supplied quarters. Management reported: “This quarter, we sharpened our commercial focus, delivered sequential revenue growth, maintained commercial profitability, and laid the foundation for a return to meaningful growth in 2027.” “At the same time, our commercially profitable regional business provides a stable foundation, with several near-term opportunities expected to support future growth.””
Develop internally originated global clinical programs, including zoci in oncology and ZL-1503 in immunology, through clinical and registrational milestones.
Over the trailing year it converted 1.15x of net income into operating cash flow.
Most sensitive to the broad stock market.
Not enough signal to read sensitivity to the US dollar, Fed net liquidity, real (inflation-adjusted) rates, long-term interest rates (low R² over the window).
8 material management or governance events in the past 24 months, led by capital-allocation actions. Historically, Health Care names rated neutral grew net income 46% of the time over the next year (vs 44% for the rest of the cohort, n=13229).
Not investment advice. As of 2026-11-04.
“This quarter, we sharpened our commercial focus, delivered sequential revenue growth, maintained commercial profitability, and laid the foundation for a return to meaningful growth in 2027.”
“At the same time, our commercially profitable regional business provides a stable foundation, with several near-term opportunities expected to support future growth.””
““Supported by national guidelines and an addressable population of ~8 million schizophrenia patients, KarXT’s launch positions us to bring the first novel therapy in decades to this critical market,…”
“This quarter, we sharpened our commercial focus, delivered sequential revenue growth, maintained commercial profitability, and laid the foundation for a return to meaningful growth in 2027.”
“At the same time, our commercially profitable regional business provides a stable foundation, with several near-term opportunities expected to support future growth.””